Literature DB >> 24664538

Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias.

Virinder Kaur Sarhadi1, Leo Lahti, Ilari Scheinin, Pekka Ellonen, Eeva Kettunen, Massimo Serra, Katia Scotlandi, Piero Picci, Sakari Knuutila.   

Abstract

Genetic alterations affecting 9p are commonly present in many cancer types and many cancer-related genes are located in this chromosomal region. We sequenced all of the genes located in a 32Mb region of 9p by targeted next generation sequencing (NGS) in 96 patients with different cancer types, including acute lymphoblastic leukemia, bone malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma, fibrosarcoma, Ewing's sarcoma, and lung carcinoma. Copy number alterations (CNA), and mutations were studied from the NGS data. We detected a deletion at the CDKN2A locus as being the most frequent genetic alteration in all cancer types. In addition to this locus, NGS also identified other small regions of copy number loss and gain. However, different cancer types did not reveal any statistically significant differences with regard to CNA frequency or type. Of the 191 genes within the target region, two novel recurrent mutations were found in the MELK and PDCD1LG2 genes. The most commonly mutated gene in sarcomas was TLN1 (8%) and PAX5 in ALL (9%). Mutations in PAX5, and RUSC2, were seen exclusively in ALL patients and those in KIAA1432, CA9, TLN1, and MELK only in sarcomas (MFH, FS, EFT). Thus using targeted NGS of the 9p region, in addition to commonly deleted CDKN2A locus, we were able to identify a number of small deletions and gains, as well as novel recurrent mutations in different cancer types. © 2014 Wiley Periodicals, Inc.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24664538     DOI: 10.1002/gcc.22168

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

Review 1.  The role of Pax5 in leukemia: diagnosis and prognosis significance.

Authors:  Mohammad Shahjahani; Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Farzaneh Tavakoli; Ali Amin Asnafi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

2.  Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.

Authors:  Suyoun Chung; Kyoko Kijima; Aiko Kudo; Yoshiko Fujisawa; Yosuke Harada; Akiko Taira; Naofumi Takamatsu; Takashi Miyamoto; Yo Matsuo; Yusuke Nakamura
Journal:  Oncotarget       Date:  2016-04-05

3.  Identification of IL11RA and MELK amplification in gastric cancer by comprehensive genomic profiling of gastric cancer cell lines.

Authors:  Danielle Queiroz Calcagno; Sylvia Santomi Takeno; Carolina Oliveira Gigek; Mariana Ferreira Leal; Fernanda Wisnieski; Elizabeth Suchi Chen; Taíssa Maíra Thomaz Araújo; Eleonidas Moura Lima; Maria Isabel Melaragno; Samia Demachki; Paulo Pimentel Assumpção; Rommel Rodriguez Burbano; Marília Cardoso Smith
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

4.  Long noncoding RNA LINC02418 regulates MELK expression by acting as a ceRNA and may serve as a diagnostic marker for colorectal cancer.

Authors:  Yinghui Zhao; Tiantian Du; Lutao Du; Peilong Li; Juan Li; Weili Duan; Yunshan Wang; Chuanxin Wang
Journal:  Cell Death Dis       Date:  2019-07-29       Impact factor: 8.469

5.  MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.

Authors:  Qinyang Xu; Qiulin Ge; Yang Zhou; Bikang Yang; Qin Yang; Shuheng Jiang; Rongzhen Jiang; Zhihong Ai; Zhigang Zhang; Yincheng Teng
Journal:  EBioMedicine       Date:  2020-01-06       Impact factor: 8.143

6.  Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer.

Authors:  Ashley A Hardeman; Yoo Jane Han; Tatyana A Grushko; Jeffrey Mueller; Maria J Gomez; Yonglan Zheng; Olufunmilayo I Olopade
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

7.  Development and Validation of Tumor-educated Blood Platelets Integrin Alpha 2b (ITGA2B) RNA for Diagnosis and Prognosis of Non-small-cell Lung Cancer through RNA-seq.

Authors:  Shan Xing; Tao Zeng; Ning Xue; Yi He; Yan-Zhen Lai; Hui-Lan Li; Qi Huang; Shu-Lin Chen; Wan-Li Liu
Journal:  Int J Biol Sci       Date:  2019-07-24       Impact factor: 6.580

8.  CircRNA_400029 promotes the aggressive behaviors of cervical cancer by regulation of miR-1285-3p/TLN1 axis.

Authors:  Yue Ma; Jing Liu; Zhuo Yang; Peng Chen; Dan-Bo Wang
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.